Congenital adrenal hyperplasia (CAH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Congenital adrenal hyperplasia (CAH)

Congenital adrenal hyperplasia (CAH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH is subcategories into classical CAH and non-classical CAH. About 75% of people with classical CAH due to 21-hydroxylase deficiency also have a deficiency of  the hormone aldosterone, leading to the inability to retain salt and water (salt wasting). The remaining 25% are referred to as simple-virilizers and do not have a problem regulating salt and water levels.

According to Thelansis Epidemiology study, the most common form of CAH, 21 hydroxylase deficiency, affects approximately 1:10,000 to 1:15,000 people in the United States and Europe. In contrast, non-classical CAH affects approximately 1 in 100 to 1 in 200 individuals in the general population.

Competitive landscape of Congenital adrenal hyperplasia (CAH) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Congenital adrenal hyperplasia (CAH) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Congenital adrenal hyperplasia (CAH) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Congenital adrenal hyperplasia (CAH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. No        Asset        Company                             Stage

1     Chronocort        Diurnal Group PLC                        Phase III

2        Nevanimibe        Millendo Therapeutics, Inc.        Phase IIb

3        NBI-74788        Neurocrine Biosciences, Inc.  Phase II

4        SPR-001               Spruce Biosciences, Inc.                Phase II